Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30866199 | 0.90 | NR2E1 (0.52) | NR2E1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL21754369 | 0.75 | NR2E1 (0.75) | NR2E1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL13081976 | 0.72 | SSTR4 (0.50) | KMT2A | |
| SCHEMBL10639172 | 0.72 | KDM4E (0.69) | NR2E1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL21333954 | 0.72 | ANPEP (0.55) | KDM4ECYP1A2CYP2C9CYP2C19HSD17B10 | |
| SCHEMBL1877421 | 0.72 | KDM4E (0.69) | NR2E1KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL4738583 | 0.72 | KMT2A (0.49) | NR2E1KDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL866593 | 0.71 | KMT2A (0.60) | KDM4EALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL14223540 | 0.71 | KMT2A (0.60) | KDM4EALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL700531 | 0.70 | NR2E1 (1.00) | NR2E1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340575-B2 | Agonists and antagonists of the urotensinergic system | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2016-05-17 | — | — | US | disclosed |
| US-9340575-B2 | Agonists and antagonists of the urotensinergic system | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2016-05-17 | — | — | US | disclosed |
| EP-2729184-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | Institut National de la Recherche Scientifique (CA) | 2014-05-14 | — | — | EP | disclosed |
| US-20140113872-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2014-04-24 | — | — | US | disclosed |
| US-20140113872-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2014-04-24 | — | — | US | disclosed |
| WO-2012149644-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2012-11-08 | — | — | WO | disclosed |
| US-20120101257-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | UNIVERSITE DE MONTREAL (CA) | 2012-04-26 | — | — | US | disclosed |
| EP-2408759-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | Valorisation-Recherche, Société en Commandite (CA) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010105367-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | VALORISATION-RECHERCHE SOCIETE EN COMMANDITE (CA) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101257-A1 | PROCESSES FOR PREPARING AMINO-SUBSTITUTED GAMMA-LACTAMS | QPCT, GLUL, ASNS | NR2E1 4122/4885KDM4E 3662/4885CYP1A2 2139/4885 |
| US-20140113872-A1 | NOVEL AGONISTS AND ANTAGONISTS OF THE UROTENSINERGIC SYSTEM | UTS2R, SCTR, PLAUR | NR2E1 426/4885KDM4E 4359/4885CYP1A2 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.